---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-113986"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:02:00.200106+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Iterum shareholders reject say-on-pay, share increase, and equity plan at AGM

## Summary
- David Kelly elected Class I director with 10.8M for, 2.8M against, 0.7M abstain, 8.2M broker non-votes.
- Say-on-pay failed: 5.4M for (38.5%), 8.4M against, 0.5M abstain.
- Share capital increase to $2.6M (add 80M shares) rejected: 6.5M for, 15.8M against.
- Equity incentive plan amendment to add 4M shares rejected: 2.5M for, 11.3M against.
- Allotment authority and pre-emption opt-out also failed by wide margins.

## SEC filing metadata
- accession: 0000950170-25-113986
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025113986/0000950170-25-113986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025113986/itrm-20250910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-113986
- JSON: https://secwatch.observer/filing/0000950170-25-113986.json
- Plain text: https://secwatch.observer/filing/0000950170-25-113986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.